Title: Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017 Document date: 2017_11_7
ID: roslkxeq_172
Snippet: Disclosures: Disclosures to report. Cabergoline is a dopamine 2 receptor (D2R) agonist which is a second line medical therapy for human acromegalic patients. Pasireotide, a somatostatin analogue, is the only effective medical management option for feline acromegaly but its cost is a limiting factor for many owners. Our work has demonstrated dopamine receptors within the feline acromegalic pituitary and we hypothesized that cabergoline would impro.....
Document: Disclosures: Disclosures to report. Cabergoline is a dopamine 2 receptor (D2R) agonist which is a second line medical therapy for human acromegalic patients. Pasireotide, a somatostatin analogue, is the only effective medical management option for feline acromegaly but its cost is a limiting factor for many owners. Our work has demonstrated dopamine receptors within the feline acromegalic pituitary and we hypothesized that cabergoline would improve diabetic control and IGF-1 concentrations of diabetic acromegalic cats.
Search related documents:
Co phrase search for related documents- dopamine receptor and somatostatin analogue: 1
Co phrase search for related documents, hyperlinks ordered by date